第一单位：
Department of Internal Medicine III, Ulm University Hospital, Ulm, Germany.;Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
作者：
Stephan R,Bohl [1]
;
Laura K,Schmalbrock [2]
;
Imke,Bauhuf [3]
;
Tatjana,Meyer [3]
;
Anna,Dolnik [4]
;
Martin,Szyska [4]
;
Tamara J,Blätte [4]
;
Sarah,Knödler [3]
;
Linda,Röhner [3]
;
Denise,Miller [3]
;
Miriam,Kull [3]
;
Christian,Langer [5]
;
Hartmut,Döhner [3]
;
Anthony,Letai [6]
;
Frederik,Damm [4]
;
Dirk,Heckl [7]
;
Lars,Bullinger [8]
;
Jan,Krönke [9]
作者单位：
Department of Internal Medicine III, Ulm University Hospital, Ulm, Germany.;Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
[1]
Department of Internal Medicine III, Ulm University Hospital, Ulm, Germany.;Department of Hematology, Oncology and Tumor Immunology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.;Berlin Institute of Health at Charité-Universitätsmedizin Berlin, Berlin, Germany.
[2]
Department of Internal Medicine III, Ulm University Hospital, Ulm, Germany.
[3]
Department of Hematology, Oncology and Tumor Immunology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
[4]
Department of Hematology, Internal Oncology and Palliative Care, Kempten Hospital, Kempten, Germany; and.
[5]
Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
[6]
Department of Hematology and Oncology Children's Hospital, Halle University Hospital, Halle, Germany.
[7]
Department of Hematology, Oncology and Tumor Immunology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.;Berlin Institute of Health at Charité-Universitätsmedizin Berlin, Berlin, Germany.
[8]
Department of Internal Medicine III, Ulm University Hospital, Ulm, Germany.;Department of Hematology, Oncology and Tumor Immunology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
[9]
DOI
10.1182/bloodadvances.2020003541
PMID
33950175
发布时间
2024-08-10
换一批
